GSK Strikes Another Antimicrobial Deal, Paying $90M for Scynexis’s Brexafemme

GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.